DE69807349T2 - Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren - Google Patents

Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren

Info

Publication number
DE69807349T2
DE69807349T2 DE69807349T DE69807349T DE69807349T2 DE 69807349 T2 DE69807349 T2 DE 69807349T2 DE 69807349 T DE69807349 T DE 69807349T DE 69807349 T DE69807349 T DE 69807349T DE 69807349 T2 DE69807349 T2 DE 69807349T2
Authority
DE
Germany
Prior art keywords
tumors
ketone
analoga
thyroxin
vicious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69807349T
Other languages
English (en)
Other versions
DE69807349D1 (de
Inventor
Ernest Kun
Jerome Mendeleyev
G Buki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of DE69807349D1 publication Critical patent/DE69807349D1/de
Application granted granted Critical
Publication of DE69807349T2 publication Critical patent/DE69807349T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
DE69807349T 1997-10-23 1998-10-23 Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren Expired - Lifetime DE69807349T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/956,711 US5922775A (en) 1997-10-23 1997-10-23 Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
PCT/US1998/022383 WO1999020263A1 (en) 1997-10-23 1998-10-23 Thyroxine analogues having no significant hormonal activity to treat malignant tumors

Publications (2)

Publication Number Publication Date
DE69807349D1 DE69807349D1 (de) 2002-09-26
DE69807349T2 true DE69807349T2 (de) 2003-01-02

Family

ID=25498590

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69807349T Expired - Lifetime DE69807349T2 (de) 1997-10-23 1998-10-23 Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren

Country Status (7)

Country Link
US (1) US5922775A (de)
EP (1) EP1024800B1 (de)
AT (1) ATE222489T1 (de)
AU (1) AU1195499A (de)
DE (1) DE69807349T2 (de)
ES (1) ES2181298T3 (de)
WO (1) WO1999020263A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
IL138572A0 (en) * 1998-03-25 2001-10-31 Biosource Genetics Corp Benzoate derivatives and pharmaceutical compositions containing the same
US6326402B1 (en) 1998-08-12 2001-12-04 Octamer, Inc. Methods for treating viral infections using a compound capable of inhibiting microtubules
US6677473B1 (en) 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
KR20060109926A (ko) * 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
EP1890768A2 (de) * 2005-05-26 2008-02-27 Metabasis Therapeutics, Inc. Neue phosphinsäurehaltige thyromimetika
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662335A1 (en) * 2006-09-05 2008-03-13 Valeria Ossovskaya Methods for designing parp inhibitors and uses thereof
EP2059498A4 (de) 2006-09-05 2011-01-12 Bipar Sciences Inc Krebsbehandlung
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
EP2217227B1 (de) 2007-11-12 2013-08-21 BiPar Sciences, Inc. Behandlung von brustkrebs mit 4-iodo-3-nitrobenzamid in kombination mit antitumoralen mitteln
JP2011521618A (ja) * 2008-02-04 2011-07-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ仲介疾患を診断および治療する方法
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
WO2018144870A1 (en) * 2017-02-03 2018-08-09 The Regents Of The University Of California Compositions and methods for inhibiting reticulon 4
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
EP3655418A4 (de) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Verfahren zur behandlung von glioblastom
EP3687501A4 (de) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Iniparib-formulierungen und verwendungen davon
MX2020009843A (es) 2018-03-22 2020-12-11 Viking Therapeutics Inc Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
EP3841091A1 (de) * 2018-08-24 2021-06-30 Xeniopro GmbH Phenoxy(hetero)arylether mit antiproliferativer wirkung
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB643089A (en) * 1947-10-23 1950-09-15 Glaxo Lab Ltd Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers
GB642159A (en) * 1947-10-23 1950-08-30 Glaxo Lab Ltd Improvements in or relating to the preparation of diphenyl ethers
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
GB9211415D0 (en) * 1992-05-29 1992-07-15 Ici Plc Process for the production of purified terephthalic acid
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
DE69807349D1 (de) 2002-09-26
WO1999020263A1 (en) 1999-04-29
EP1024800A1 (de) 2000-08-09
AU1195499A (en) 1999-05-10
ES2181298T3 (es) 2003-02-16
ATE222489T1 (de) 2002-09-15
EP1024800B1 (de) 2002-08-21
US5922775A (en) 1999-07-13

Similar Documents

Publication Publication Date Title
DE69807349D1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
ATE300292T1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69127175D1 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE196847T1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE249233T1 (de) Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen
ATE257378T1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
NO994330L (no) Metode for behandling av en tumor
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
SE9601395D0 (sv) New therapeutic treatment 1
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
DE69924979D1 (de) Behandlung von chronischen schmerzen
ATE159171T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: OCTAMER, INC., TIBURON, CARLIF., US

8364 No opposition during term of opposition